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MinireviewThe Pancreatic  Cell Heats Up:
UCP2 and Insulin Secretion
in Diabetes
is present in brown adipose tissue (Klingenberg and
Huang, 1999). More recently UCP2 (Fleury et al., 1997)
and UCP3 (Vidal-Puig et al., 1997) have been identified.
These proteins are homologous to UCP1, appear to be-
have as uncoupling proteins (albeit with less activity
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than UCP1) in mitochondria, but have a very different
tissue distribution. UCP2 is expressed in many tissues,
including the pancreatic  cell. UCP3 is expressed pri-The pancreatic  cell is a highly specialized cell that
marily in muscle. Adenoviral overexpression of UCP2 innormally responds to small changes in the blood glu-
insulin secreting cells and rat islets leads to the pre-cose concentration by regulating insulin secretion to
dicted uncoupling of oxidative phosphorylation and anmaintain blood glucose within a narrow physiological
impairment of glucose-induced insulin secretion (Chanrange (Matschinsky et al., 1998). When glucose concen-
et al., 1999).trations increase, as they do after ingestion of a meal,
In this issue of Cell, Zhang and coworkers (Zhang etinsulin secretion increases. With fasting, insulin secre-
al., 2001) extend these observations to the physiologicaltion is suppressed. Insulin gene transcription plays an
situation in an elegant and important series of studies.important role in maintaining sufficient insulin stores in
Gene targeting in embryonic stem cells was used tosecretory granules. However, the release of insulin from
generate UCP2-deficient mice. Homozygous (/) ani-secretory granules in response to the minute-to-minute
mals failed to express intact UCP2 mRNA in all tissuesfluctuations in blood glucose depends on a complex
tested, including pancreatic islets. UCP2 mRNA wassignal transduction pathway linked to glucose metabo-
reduced in islets isolated from heterozygous (/) ani-
lism (Ashcroft and Gribble, 1999).
mals compared with controls. Deficiency of UCP2 had
Like other cells, pancreatic  cells metabolize glucose
no effects on body weight or cold-induced thermogene-
to yield ATP. The metabolism of glucose generates elec-
sis in the mutant mice. The mice lacking UCP2 had
tron carriers (such as NADH) that shuttle to the inner
significantly lower glucose levels and higher insulin se-
membrane of the mitochondrion, where they donate
cretion rates under basal conditions and following intra-
electrons to the electron transport chain. As electrons peritoneal and intravenous glucose administration. Pan-
move down this chain, protons are pumped out of the creatic islets isolated from the homozygous (/)
mitochondrial matrix by complexes I, III, and IV, creating animals secreted more insulin and demonstrated higher
a proton electrochemical gradient (Scheffler, 1999). The levels of ATP than control animals. These results sug-
potential energy in this gradient is used by ATP synthase gest that the level of Ucp2 gene expression in the pan-
to produce ATP from ADP. In the  cell, the increase in creatic  cell is an important determinant of the sensitiv-
the ATP/ADP ratio that results from glucose metabolism ity of insulin secretion to changes in glucose.
closes a membrane ATP-sensitive potassium channel, On the basis of additional studies performed in ob/
causing membrane depolarization, calcium influx, and ob mice, a model of type 2 diabetes, the authors suggest
insulin secretion. Normally, the generation of ATP is that UCP2 is a major link between obesity,  cell dys-
tightly coupled to the metabolism of glucose and the function, and type 2 diabetes. UCP2 mRNA and protein
two processes proceed in parallel. Thus, the secretion were upregulated in pancreatic islets from ob/ob mice.
of insulin is linked to the rate of glucose metabolism Although serum insulin levels were elevated 33-fold in
through oxidative phosphorylation. Defects in oxidative these animals, even this marked degree of hyperinsulin-
phosphorylation would be expected to impair insulin emia was insufficient to compensate for the profound
secretion. Consistent with this notion, mitochondrial insulin resistance, resulting in significant hyperglycemia,
mutations cause maternally inherited type 2 diabetes particularly following glucose administration. When
due to defects in insulin secretion (Guillausseau et al., mice lacking UCP2 were crossed with ob/ob mice, the
2001; Velho et al., 1996). Uncoupling glucose metabo- resulting reduction in UCP2 expression in the ob/ob
lism from ATP generation would also be expected to animals was associated with a marked improvement in
impair the ability of the  cell to secrete insulin in re- glucose tolerance. This genetically induced reduction
sponse to glucose. Reducing the extent of uncoupling of UCP2 levels in ob/ob mice had effects on insulin
would be expected to increase insulin secretion. concentrations that were dependent on the experimen-
A family of proteins located in the inner mitochondrial tal conditions. In the fed state, there was a significant
membrane that act as proton channels or transporters fall in blood glucose and a significant increase in serum
have been identified, as recently reviewed (Skulachev, insulin levels. Fasting glucose levels were lower in the
ob/ob mice lacking UCP2 and, although there was a1998). They uncouple biochemical respiration from oxi-
tendency for fasting insulin levels to fall as well in thesedative phosphorylation by leaking protons into the mito-
animals, differences were not significantly lower than inchondrial matrix, bypassing ATP synthase and resulting
control ob/ob mice. Following intraperitoneal glucosein the generation of heat rather than the formation of
administration, blood glucose and serum insulin levelsATP. The first of these proteins to be discovered, UCP1,
were both significantly lower in the ob/ob mice lacking
UCP2 than in control ob/ob mice, except at the 15 mi-
nute time point, when insulin concentrations were signif-1 Correspondence: polonsky@im.wustl.edu
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icantly higher, suggesting a significant improvement in populations, insulin resistant obese subjects are able
to maintain normal glucose tolerance for prolonged peri-the rapid insulin secretory response to glucose. On the
basis of these results, the authors conclude that the ods of time through this mechanism of  cell compensa-
tion. In a proportion of subjects, compensation fails,improvement in glucose tolerance seen in the ob/ob
mice when a reduction in UCP2 levels was genetically insulin concentrations fall, and glucose concentrations
rise, eventually leading to diabetes. Does increasedinduced is due to enhanced insulin secretion. A note
of caution appears to be warranted before a definitive UCP2 expression contribute to this failure of  cell com-
pensation for insulin resistance? Although the possibilityconclusion is reached on this important point. The ef-
fects of lowering UCP2 levels in ob/ob mice on serum is intriguing, based on the data in the present paper in
Cell (Zhang et al., 2001), the effects may be subtle. De-insulin levels were complex, and insulin concentrations
were either increased or decreased depending on the spite increased expression of UCP2 in pancreatic 
cells, insulin concentrations were over 30-fold greaterphysiological state under which the animals were stud-
ied, as well as the prevailing blood glucose concentra- than control in ob/ob mice, indicating that increased
expression of UCP2 is still compatible with substantialtions. Since the techniques used by the authors in the
current paper in Cell would have eliminated UCP2 in hypersecretion of insulin. However, the rapid insulin se-
cretory response to glucose was significantly enhancedmultiple tissues in addition to the  cell, it would seem
appropriate to consider the possibility that the mecha- in ob/ob mice lacking UCP2, suggesting that the ability
of the  cell to respond to minute-to-minute fluctuationsnism of glucose lowering in ob/ob mice lacking UCP2
may be more complex than purely an increase in insulin in blood glucose may be enhanced. It will thus be impor-
tant to prospectively study animals that can and cannotsecretion, and could relate at least in part to UCP2 defi-
ciency in other tissues. compensate for insulin resistance to determine whether
 cell UCP2 levels differ in these groups over time. Ani-What have we learned about the possible role of UCP2
in the physiological regulation of insulin secretion and mal models that have similar degrees of insulin resis-
tance but different propensities to develop  cell failurein the pathophysiology of obesity and diabetes? On the
basis of the present study in Cell and other data, a and diabetes are available (Coleman, 1978). If UCP2
plays a critical role in the pathophysiology of  cellnumber of conclusions are warranted. UCP2 uncouples
oxidative phosphorylation. It is normally present in the dysfunction in type 2 diabetes, animals with diminished
 cell UCP2 expression should be protected from thepancreatic  cell of animals and plays a role in determin-
ing the  cell response to glucose, since elimination of development of diabetes when insulin resistance is in-
duced, e.g., by a high fat diet. The expression of manyUCP2 expression is associated with an increase in insu-
lin secretion, and the 50% reduction in UCP2 in hetero- genes is altered in diabetic islets (Tokuyama et al., 1995;
Weir et al., 2001) and the relative importance of in-zygous animals is associated with an intermediate phe-
notype. Adenoviral-mediated overexpression of UCP2 creased UCP2 expression in relation to the other abnor-
malities of gene expression will need to be evaluated.leads to impaired glucose-stimulated insulin secretion.
Do increases in  cell expression of UCP2 contribute to Many of the changes in the diabetic islet are induced
by hyperglycemia and are reversible with experimentalthe insulin secretory failure that develops during the
evolution of type 2 diabetes? UCP2 expression is en- interventions that lower glucose, suggesting that they
are the result rather than the cause of hyperglycemia.hanced in obese, diabetic ob/ob mice. It also increases
following exposure of pancreatic islets to free fatty acids The effects of lowering glucose in diabetic animals on
 cell UCP2 gene expression will need to be determined(Lameloise et al., 2001), a maneuver known to impair
glucose-stimulated insulin secretion with chronic treat- before UCP2 can be accepted as a major link between
obesity,  cell dysfunction, and type 2 diabetes.ment. Although these results raise the possibility that
an increase in UCP2 expression may contribute to the The suggestion that pancreatic  cell UCP2 is a useful
target for the therapy of type 2 diabetes is exciting. cell dysfunction that occurs in insulin resistant animals
or humans who develop type 2 diabetes, more informa- A reduction in UCP2 expression resulted in significant
improvements in glucose levels and insulin secretion intion is needed to substantiate this hypothesis and to
establish a clear cause-and-effect relationship between diabetic ob/ob mice. However, overexpression of UCP2
in pancreatic islets from obese insulin resistant Zuckeran increase in UCP2 and  cell dysfunction.
There is evidence that increased UCP2 expression diabetic rats, another rodent model of type 2 diabetes,
improved  cell function (Wang et al., 1999). The resultsmay not impair ATP generation in muscle. In muscle,
thyroid hormone increases UCP2 expression at the mes- of the latter study are at variance with the study by Chan
et al. (1999), which concluded that overexpression ofsage and protein levels and also increases ATP produc-
tion (Short et al., 2001). Although these results, which UCP2 induced by adenovirus in normal islets leads to
inhibition of insulin secretion, a result consistent withwere obtained in isolated mitochondria from muscle,
cannot be extrapolated to indicate that UCP2 does not the present study in Cell. Whether these discrepancies
relate to specific characteristics of the Zucker diabeticimpair ATP generation in the pancreatic  cell, they
nevertheless raise the possibility that the functional ef- islets compared to normal rat islets or reflect differences
between in vivo and in vitro models is uncertain. How-fects of increased UCP2 expression may not be com-
pletely understood. ever, it will be important to confirm in other models
that the desired therapeutic outcome in diabetes is aThe presence of insulin resistance evokes a compen-
satory increase in the secretion of insulin (Polonsky et decrease in UCP2 expression in the pancreatic  cell.
While inhibition of  cell UCP2 may lead to an increaseal., 1996). The resulting hyperinsulinemia is responsible
for maintaining normal blood glucose concentrations in in insulin secretion, there is evidence that in peripheral
tissues such as muscles, the desired therapeutic out-the face of diminished peripheral insulin action. In most
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come may be an increase in uncoupling protein. It has
been shown (Li et al., 2000) that an increase in UCP1
expression in muscle protects mice from diet-induced
weight gain due to increases in peripheral energy expen-
diture. It thus may be necessary to develop tissue-spe-
cific approaches in which it would be possible to achieve
a decrease in uncoupling protein in the pancreatic  cell
in order to stimulate insulin secretion and a simultane-
ous increase in uncoupling protein in peripheral tissues
to promote weight loss and energy expenditure in over-
weight, insulin-resistant individuals.
In summary, UCP2 appears to affect the degree of
uncoupling of respiration and oxidative phosphorylation
in the pancreatic  cell, thereby serving an important
regulatory role in insulin secretion. Additional studies
are needed to confirm the hypothesis that an increase
in UCP2 expression is an important trigger in the failure
of  cell compensation for insulin resistance, a poorly
understood event that is critical to the development of
type 2 diabetes.
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